Insider Trading March 9, 2026

Riverview Bancorp EVP Purchases Small Stake as Company Maintains Buyback and Dividend Plans

Charmaine Lightheart adds 325 shares to her holdings; firm continues $4 million repurchase program and quarterly dividend

By Sofia Navarro RVSB
Riverview Bancorp EVP Purchases Small Stake as Company Maintains Buyback and Dividend Plans
RVSB

Riverview Bancorp Inc executive Charmaine Lightheart purchased 325 shares of the bank's common stock on March 5, 2026, spending $1,742 at $5.36 per share. Following the trade she directly owns 14,893 shares and indirectly holds 443 shares via the ESOP. The company recently authorized a repurchase program for up to $4 million, keeps its quarterly dividend at $0.02 per share with a scheduled payment on January 16, 2026, and reported $1.51 billion in assets as of September 30, 2025.

Key Points

  • Executive VP Charmaine Lightheart purchased 325 shares at $5.36 on March 5, 2026, bringing her direct holdings to 14,893 shares and indirect ESOP holdings to 443 shares.
  • Riverview Bancorp has an authorized share repurchase program for up to $4 million, approved on January 22, usable in the open market or via private transactions for up to 12 months or until the limit is reached.
  • The company maintains its quarterly dividend of $0.02 per share payable January 16, 2026 to shareholders of record as of January 5, 2026, and reported $1.51 billion in assets as of September 30, 2025.

Riverview Bancorp Inc (NASDAQ:RVSB) reported an insider purchase on March 5, 2026, when Executive Vice President and Chief Retail and Deposit Executive Charmaine Lightheart bought 325 shares of the company's common stock at $5.36 per share. The total cost of the transaction was $1,742. After the acquisition, Lightheart directly holds 14,893 shares and also has an indirect interest in 443 shares held within the company ESOP.

The share price at the time of reporting is $5.39, which sits close to Lightheart's purchase price. According to InvestingPro valuation data, Riverview Bancorp is assessed as undervalued with a Fair Value estimate of $5.86. The company carries a market capitalization of $111.63 million, a price-to-earnings ratio of 23.36, and a dividend yield of 1.48%.

Riverview has sustained dividend payments for 12 consecutive years, per InvestingPro Tips. The company declared a quarterly dividend of $0.02 per share, unchanged from the prior quarter, with a scheduled payment date of January 16, 2026, to shareholders of record as of January 5, 2026. Investors seeking additional analysis can access two further ProTips on the InvestingPro platform.

In corporate actions affecting shareholder capital allocation, Riverview Bancorp authorized a new share repurchase program that permits the company to buy back up to $4 million of its outstanding common stock. The repurchase plan, approved on January 22, allows purchases in the open market or through privately negotiated transactions and remains in effect until the $4 million limit is exhausted or 12 months elapse from the effective date, whichever occurs first.

On the balance-sheet front, Riverview reported total assets of $1.51 billion as of September 30, 2025. The combination of an ongoing buyback program, a maintained quarterly dividend, and the insider purchase are factual developments that reflect recent company-level actions and executive activity, without implying future performance.


Note: This article presents reported transaction details, company financial metrics, and announced corporate actions exactly as provided in the available disclosures.

Risks

  • Size of the insider purchase is relatively small and may not materially affect market perception or share price; this pertains to investor confidence and market liquidity in the banking sector.
  • The buyback authorization is capped at $4 million and limited by a 12-month window, which constrains the program's scope to influence share supply and capital allocation decisions in the financial services sector.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026